Stocks Health care WHWK
NASDAQ · Health careWhitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. brought in $0 of revenue over the twelve months to September 30, 2026, down 100.0% from a year earlier. It posted a net loss of $83.3M. In fiscal 2025 capital spending exceeded operating cash flow by $98M. At September 30, 2026 it held $69M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Whitehawk Therapeutics, Inc.
- Net worth
- Whitehawk Therapeutics, Inc. has a market value (market cap) of $178.4M at the latest share price, and shareholders' equity of $163.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $7.1M (-72.5% year on year), with a net loss of $20.6M. Over the 12 months to September 30, 2026: revenue $0, net loss $83.3M.
- Cash flow
- In fiscal 2025 operations used $97.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Whitehawk Therapeutics, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Whitehawk Therapeutics, Inc. does
Whitehawk Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker WHWK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.1M | -$20.6M | -$0.33 | -$98M |
| 2024 | $26M | -$63.7M | -$2.36 | -$61.2M |
| 2023 | $24.4M | -$65.8M | -$2.44 | -$63.6M |
| 2022 | $15.2M | -$60.5M | -$2.69 | -$50.1M |
| 2021 | $14M | -$110.1M | -$12.41 | -$22.5M |
| 2020 | $14M | -$3.5M | -$1.76 | -$12.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where WHWK ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2022 | n/a | $0 | n/a |
| 2021 | n/a | $4.4M | n/a |
Latest SEC filings
What Whitehawk Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- September 10, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- June 12, 2026
- May 29, 2026
- May 21, 2026Other event 8-K
Insider trades
What the people running Whitehawk Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 14, 2026 | Dalal AnupamDirector | Received as payindirect | 1,275,510 | $5M |
| May 14, 2026 | Castelein CaleyDirector | Received as pay | 255,102 | $1M |
| May 14, 2026 | Giacobello Scott M.CHIEF FINANCIAL OFFICER | Received as pay | 38,265 | $150K |
| May 14, 2026 | Ball BryanSee remarks | Received as pay | 51,020 | $200K |
| May 14, 2026 | Dugan MargaretChief Medical Officer | Received as pay | 19,132 | $75K |
| May 14, 2026 | Lennon David JamesCHIEF EXECUTIVE OFFICER, Director | Received as pay | 51,021 | $200K |
| April 16, 2026 | Giacobello Scott M.CHIEF FINANCIAL OFFICER | Sold | 141,600 | $584.8K |
| April 15, 2026 | Giacobello Scott M.CHIEF FINANCIAL OFFICER | Sold | 77,000 | $297.2K |
Who owns WHWK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Behzad Aghazadeh13D, may seek influence with 2 related filers | 19.99% | May 14, 2026 |
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 9.99% | March 11, 2025 |
| Fan Yu13G, passive with 12 related filers | 9.4% | August 14, 2026 |
| QVT Financial LP13G, passive | 9.37% | February 14, 2025 |
| Anupam Dalal13D, may seek influence with 2 related filers | 9% | May 18, 2026 |
| OrbiMed Advisors LLC13G, passive with 1 related filers | 7.3% | August 14, 2026 |
| Coastlands Capital LP13G, passive with 4 related filers | 5.98% | August 25, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 78 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Yu Fan | 4,861,314 | +2,791,314 |
| Acuta Capital Partners, LLC | 4,685,912 | +1,275,510 |
| QVT Financial LP | 4,615,709 | 0 |
| Montanova Capital, LLC | 4,300,000 | +600,000 |
| Orbimed Advisors LLC | 3,934,296 | -231,704 |
| Avoro Capital Advisors LLC | 2,849,402 | 0 |
| Siren, L.L.C. | 2,337,102 | +255,102 |
| KVP Capital Advisors, LP | 2,165,997 | 0 |
| BlackRock, Inc. | 1,922,828 | +1,571,443 |
| Vanguard Capital Management LLC | 1,388,561 | +72,791 |
| ADAR1 Capital Management, LLC | 1,341,394 | +1,212,891 |
| Acorn Capital Advisors, LLC | 1,139,363 | 0 |
| Stempoint Capital LP | 1,021,037 | -857,701 |
| Geode Capital Management, LLC | 899,780 | +442,240 |
| Ally Bridge Group (NY) LLC | 817,939 | 0 |
| Woodline Partners LP | 436,614 | +155,117 |
| Renaissance Technologies LLC | 413,822 | -14,800 |
| State Street Corp | 386,982 | +226,600 |
| Millennium Management LLC | 380,406 | +70,732 |
| Eversept Partners, LP | 303,306 | -3,494 |
Insiders
6 insiders reported holding 6,331,098 shares in total, about $19.8M at the last price.
| Holder | Shares |
|---|---|
| Dalal AnupamDirector | 4,685,9124,685,912 held indirectly |
| Lennon David JamesCHIEF EXECUTIVE OFFICER, Director | 569,643 |
| Ball BryanSee remarks | 448,126 |
| Giacobello Scott M.CHIEF FINANCIAL OFFICER | 333,489 |
| Castelein CaleyDirector | 274,796 |
| Dugan MargaretChief Medical Officer | 19,132 |
Questions about WHWK
What does Whitehawk Therapeutics, Inc. do?
Whitehawk Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as WHWK. Its shares trade on NASDAQ under the ticker WHWK.
What is Whitehawk Therapeutics, Inc.'s net worth?
Whitehawk Therapeutics, Inc. has a market value (market cap) of $178.4M at the latest share price, and shareholders' equity of $163.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Whitehawk Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $83.3M.
How much revenue does Whitehawk Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Whitehawk Therapeutics, Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Whitehawk Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Whitehawk Therapeutics, Inc.'s next earnings report?
Whitehawk Therapeutics, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare WHWK with
Follow WHWK
Get an email when Whitehawk Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Whitehawk Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.